-+ 0.00%
-+ 0.00%
-+ 0.00%

Arcutis Biotherapeutics To Present New Data From Its Clinical Development Program And Marketed ZORYVE Portfolio

Benzinga·03/18/2026 12:06:25
Listen to the news

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will present new data from its clinical development program and marketed ZORYVE® (roflumilast) portfolio during the 2026 American Academy of Dermatology (AAD) Annual Meeting taking place March 27-31 in Denver.